Modified-Release Huperzine Formulation for Peak Plasma Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immediate release formulations of huperzine A cause dose-limiting adverse events such as nausea and vomiting due to rapid plasma exposure, necessitating frequent dosing and making compliance difficult in patients with chronic conditions, while existing slow release formulations fail to reduce peak plasma concentrations and require multiple daily doses.
Innovation Solution
A modified release pharmaceutical composition comprising a sugar sphere core coated with huperzine and a plasticized ethyl cellulose polymer layer, designed to provide a therapeutically effective amount of huperzine with controlled plasma concentration and reduced peak levels, allowing for twice-daily dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation of huperzine A is used, then rapid plasma exposure and therapeutic effect are achieved, but dose-limiting adverse events (nausea and vomiting) occur and frequent dosing is required
Solution Approach 1:
The patent segments the huperzine A dosage into multiple smaller doses administered throughout the day. Each capsule contains a controlled amount of huperzine A that is released gradually, preventing the rapid plasma exposure that causes adverse events while maintaining therapeutic efficacy through sustained drug levels.
Solution Approach 2:
The patent implements periodic administration of huperzine A at scheduled intervals (multiple times daily). This periodic dosing strategy maintains steady plasma concentrations within the therapeutic window, avoiding both the rapid peaks that cause nausea/vomiting and the troughs that would reduce efficacy.
2Reliability
If higher doses of huperzine A are administered, then therapeutic efficacy is improved, but dose-related adverse events increase
Solution Approach 1:
The patent changes the dosing parameters by administering higher total daily doses of huperzine A but distributing them across multiple smaller administrations throughout the day. This parameter change allows achieving higher overall therapeutic exposure while keeping individual dose-related plasma concentrations within the tolerable range, thus reducing adverse events.
3Reliability
If immediate release formulation is used, then full therapeutic effect is achieved quickly, but compliance becomes difficult due to frequent dosing requirements
Solution Approach 1:
The patent segments the total daily therapeutic dose into multiple smaller capsules that can be taken at convenient intervals throughout the day. This segmentation makes the dosing regimen more manageable and compliant for patients, as smaller, more frequent doses are easier to incorporate into daily routines compared to large single doses.
4Duration of action of moving object
If existing slow release formulations are used, then dosing frequency is reduced, but peak plasma concentrations are not significantly reduced
Solution Approach 1:
The patent employs periodic administration of controlled amounts of huperzine A at scheduled intervals. This periodic dosing approach, combined with the encapsulated formulation, achieves both extended duration of action and controlled peak plasma concentrations by releasing the drug gradually over time rather than all at once.
Data Source
AI summary
The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.